• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunovant Inc (NQ: IMVT )

    27.44 -0.05 (-0.18%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,234,100
    Open 27.17
    Bid (Size) 25.51 (1)
    Ask (Size) 28.00 (15)
    Prev. Close 27.49
    Today's Range 26.83 - 28.57
    52wk Range 16.58 - 45.58
    Shares Outstanding 114,998,871
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
    Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
    Via InvestorPlace
    Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
    Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
    Via Investor's Business Daily

    Performance

    YTD
    -33.70%
    -33.70%
    1 Month
    -13.19%
    -13.19%
    3 Month
    -30.21%
    -30.21%
    6 Month
    -16.65%
    -16.65%
    1 Year
    +55.73%
    +55.73%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
    Via InvestorPlace
    Recap: Immunovant Q3 Earnings
    Via Benzinga
    Argenx Dives On Autoimmune Therapy Failure
    Via Investor's Business Daily
    Analyst Ratings for Immunovant
    Via Benzinga
    Where Immunovant Stands With Analysts
    Via Benzinga
    Recap: Immunovant Q2 Earnings
    Via Benzinga
    7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
    Via InvestorPlace
    3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
    Via InvestorPlace
    5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
    Via The Motley Fool
    Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
    Via Investor's Business Daily
    The Latest Analyst Ratings for Immunovant
    Via Benzinga
    Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
    Via Investor's Business Daily
    Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
    Via Benzinga
    Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
    From Roivant Sciences
    Via GlobeNewswire
    Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
    Via Investor's Business Daily
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
    From Roivant Sciences
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.